Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo.

Experimental cell research - 15 Mar 2020

Ni Jie, Cheung Belamy B, Beretov Julia, Duan Wei, Bucci Joseph, Malouf David, Graham Peter, Li Yong

Abstract excerpt

We have previously demonstrated that CD44 variant 6 (CD44v6) is associated with prostate cancer (CaP) growth and therapeutic resistance in vitro, however, the role of CD44v6 in CaP in vivo is not fully understood. The purpose of this study is to investigate the effect of CD44v6 on CaP growth and chemo-/radiotherapy response in NOD/SCID mouse models in vivo and to validate its role as a therapeutic target for CaP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemoradiotherapy
Share to Docetaxel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gamma Rays

Share to Hyaluronan Receptors

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Radiation Tolerance

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 31954695
DOI: 10.1016/j.yexcr.2020.111850

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo.PMID 31954695Read ↗

CD44v6 Promotes Proliferation, Migration, and Invasion in Cholangiocarcinoma Cells, but Lacks Independent Prognostic SignificanceSemantic proximity Read ↗

CDCA5 promotes the progression of prostate cancer by affecting the ERK signalling pathwaySemantic proximity Read ↗

CD44 and its implication in neoplastic diseasesSemantic proximity Read ↗

Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMTSemantic proximity Read ↗

CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancerSemantic proximity Read ↗

Generation of a stable anti-human CD44v6 scFv and analysis of its cancer-targeting ability in vitroSemantic proximity Read ↗

Transcription Factor Stat3 Stimulates Metastatic Behavior of Human Prostate Cancer Cells in Vivo, whereas Stat5b Has a Preferential Role in the Promotion of Prostate Cancer Cell Viability and Tumor GrowthSemantic proximity Read ↗

A Genome-Wide RNAi Screen Identifies FOXO4 as a Metastasis-Suppressor through Counteracting PI3K/AKT Signal Pathway in Prostate CancerSemantic proximity Read ↗

Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer CellsSemantic proximity Read ↗

Integrative analysis of the ST6GALNAC family identifies GATA2-upregulated ST6GALNAC5 as an adverse prognostic biomarker promoting prostate cancer cell invasionSemantic proximity Read ↗

Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.Semantic proximity Read ↗

Development of a Novel Anti-CD44 variant 6 Monoclonal Antibody for Multiple Applications against Colorectal CarcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.